Virax Biolabs (US:VRAX) Prnewswire·2024-08-29 13:03Company Overview - Virax Biolabs Group Limited is an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases [4] - The company is developing T-Cell-based test technologies aimed at providing an immunology profiling platform, particularly effective for diagnosing post-viral syndromes like Long COVID and other chronic conditions linked to immune dysregulation [4] Event Participation - The company will host a booth at the 7th European Congress of Immunology (ECI) from September 1 - 4, 2024, in Dublin, Ireland [1] - Virax will showcase its portfolio of immune profiling products for research use at Booth C13, with management available for discussions with research organizations and potential customers [2] Industry Context - The European Congress of Immunology is a triennial joint meeting of all European Federation of Immunological Societies (EFIS), regarded as one of the most prestigious international conferences in basic and clinical immunology, attracting over 3,000 delegates [3] - The theme for this year's congress is 'Conquering challenges with Immunology' [3]